Hypoxia-inducible factor-1α, vascular endothelial growth factor, inducible nitric oxide synthase, and endothelin-1 expression correlates with angiogenesis in congenital heart disease  by Yin, Hsin-Ling et al.
Kaohsiung Journal of Medical Sciences (2016) 32, 348e355Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEHypoxia-inducible factor-1a, vascular endothelial
growth factor, inducible nitric oxide synthase,
and endothelin-1 expression correlates with
angiogenesis in congenital heart disease
Hsin-Ling Yin a,b,c, Chi-Wen Luo c, Zen-Kong Dai d,e, Kai-Ping Shaw f,
Chee-Yin Chai b,c, Chun-Chieh Wu c,*a Division of Forensic Pathology, Department of Pathology, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
b Department of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan
c Division of Anatomic Pathology, Department of Pathology, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
d Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical
University, Kaohsiung, Taiwan
e Department of Pediatrics, Faculty of Medicine, College of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan
f Department of Forensic Pathology, Institute of Forensic Medicine, Ministry of Justice,
Taipei, TaiwanReceived 4 February 2016; accepted 25 May 2016







growth factorConflicts of interest: All authors d
* Corresponding author. Department
E-mail address: lazzz_wu@yahoo.c
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2016, Kaohsiu
CC BY-NC-ND license (http://creativeAbstract In Taiwan, the average prevalence of congenital heart disease (CHD) is 13.08/1000
live births. Most children with CHD die before the age of 5 years; therefore, identifying treat-
ment methods to extend the life of CHD patients is an important issue in clinical practice. The
objective of this study is to evaluate the roles of hypoxia-inducible factor-1a (HIF-1a), vascular
endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), endothelin-1 (ET-1),
and CD34 in CHD autopsy cases in comparison with autopsy cases without CHD. The study
included 19 autopsy cases, which were divided into the following four groups: acyanotic
CHD (n Z 11), cyanotic CHD (n Z 3), CHD associated with chromosomal abnormalities
(n Z 3), and complex CHD (n Z 2). Heart specimens obtained from 10 autopsy cases without
CHD were included as controls. Our results indicated that high percentages of HIF-1a (100%),
VEGF (89.5%), iNOS (78.9%), and ET-1 (84.2%) expressions were observed in CHD autopsy caseseclare no conflicts of interest.
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Angiogenesis in congenital heart disease 349and this was found to be significant. HIF-1a induced by hypoxia could play a potential role in
relating downstream gene expressions in CHD patients. Upregulation of VEGF by HIF-1a could
play an important role in triggering angiogenesis to protect myocardial cell survival in a hyp-
oxic microenvironment. Therefore, HIF-1a could be a significant prognosis marker in CHD
and be a prospective candidate in the development of target therapy in cardiovascular dis-
eases.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Congenital heart disease (CHD) is the most common defect
caused by abnormal cardiac formation in fetuses, with its
highest prevalence in Asia. The average incidence rate of
CHD in Taiwan is 13.08/1000 live births [1]. Ventricular
septal defect (VSD) is the most common defect, followed by
atrial septal defect (ASD), patent ductus arteriosus (PDA),
pulmonary stenosis, tetralogy of Fallot, and coarctation of
the aorta. CHD has also become the leading cause of
childhood mortality with an incidence of approximately 1%
and most CHD children die before the age of 5 years [2]. To
prolong the life of patients with CHD, cardiovascular target
therapy is promising for future treatment.
A previous study indicated that hypoxia contributes
significantly to some common diseases including CHD at the
beginning of life [3]. Hypoxia-inducible factors (HIFs) are
transcription factors that are stabilized mainly in response
to decreased oxygen availability. HIFs are composed of two
subunits (HIF-1a and HIF-1b). HIF-1a is affected by the
oxygen level, whereas HIF-1b is not. Under conditions of
normal oxygen level, HIF-1a will combine with von Hippel-
Lindau protein, targeted for ubiquitination and later
degradation by proteasome. When hypoxia occurs, HIF-1a
does not combine with von Hippel-Lindau protein but ac-
cumulates rapidly and combines with HIF-1b to form het-
erodimers, and then activates the downstream genes of
vascular endothelial growth factor (VEGF) [4], inducible
nitric oxide synthase (iNOS) [5], and endothelin-1 (ET-1)
expressions [6] in cardiomyocytes and endothelial cells,
resulting in an increase of angiogenesis.
VEGF is an endothelial-specific mitogen and plays an
important role in vascular development, angiogenesis,
collateral growth, embryonic development, wound healing,
tumor growth, inflammatory diseases, extracellular matrix
proteolysis, and ischemia. Under hypoxic conditions, VEGF
expression increases because HIF-1a binds to the hypoxic
response element in its 50 flanking region [7] and then in-
duces proliferation, sprouting, migration, and tube forma-
tion of endothelial cells.
Nitric oxide (NO) plays an important role as a regulator
in the nervous, immune, and cardiovascular systems. In
cardiac tissue, basal production of NO is maintained by
constitutive expression of endothelial NO synthase (eNOS)
and contributes to the regulation of coronary circulation,
heart rate, and myocardial contractility [8]. However, NO
generated by the inducible form of NO synthase (iNOS) has
been implicated in many pathophysiological states leadingto myocardial dysfunction. It has also been reported in
ischemia/reperfusion injury.
ET-1 is a potent vasoconstrictor and is produced by
vascular endothelial cells. Patients with heart failure have
an increased concentration of ET-1 in plasma. Increased
concentration of ET-1 causes cardiac fibroblast prolifera-
tion and recombination of extracellular matrix, besides
inducing fibrosis and leading to cardiac dysfunction. ET-1
receptor antagonists are used in the treatment of pulmo-
nary hypertension [9,10]. Inhibition of these receptors
prevents pulmonary vasculature constriction, and thus de-
creases pulmonary vascular resistance.
In this study, expressions of HIF-1a, VEGF, iNOS, and ET-1
in CHD and non-CHD autopsy cases were investigated by
immunohistochemistry (IHC) and scored using semi-
automated image analysis software. The pathological find-
ings of these maker expressions and their relationships to
the specificity in the diagnosis of CHD were also discussed.Materials and methods
Specimens
This study focused on the autopsy cases of CHD patients in
the Kaohsiung Medical University Hospital in Taiwan from
January 1975 to October 2014. All cases were fixed in
formalin, embedded in paraffin, and stored in the archives
of the Department of Pathology, Kaohsiung Medical Uni-
versity Hospital (Kaohsiung, Taiwan).
In this study, 19 CHD specimens relevant to the abnormal
part were collected from a fixed site of the left ventricle
and divided into four groups for analysis. The first group
consisted of 11 cases of acyanotic CHD (ACHD), which
mainly included PDA, VSD, and ASD cases. The second group
consisted of three cases of cyanotic CHD (CCHD; 2 cases of
left heart hypoplastic syndrome and 1 case of Eisenmenger
syndrome). The third group consisted of three cases of CHD
associated with chromosomal abnormalities with Trisomy
13, 18, and 21, respectively. The fourth group consisted of
two cases with complex CHD. Ten autopsy cases without
CHD were included as controls (Table 1). Before IHC, we
examined the ventricle tissues histologically and we did not
see any fibrosis in these tissues, which were taken relevant
to the ischemic part. Therefore, we performed IHC to un-
derstand whether there were any ischemic changes in these
tissues that could not be distinguished by hematoxylin and
eosin stain. Institutional Review Board approval for using
Table 1 Details of 19 autopsy cases with CHD and 10 autopsy cases without CHD (controls). The CHD cases (n Z 19) were
divided into four groups: (1) eleven cases of acyanotic CHD (ACHD), which mainly included PDA, VSD, and ASD cases; (2) three
cases of cyanotic CHD (CCHD; 2 cases of left heart hypoplastic syndrome and 1 case of Eisenmenger syndrome); (3) three cases
of CHD associated with chromosomal abnormalities (Trisomy 13, 18, and 21), respectively; (4) two cases with complex CHD.
No. Age Sex Clinical diagnosis [acyanotic CHD (Group 1)]
1 4 mo M VSD, pulmonary hypertension þ pneumonia
2 28 d M PDA, pulmonary atresia
3 2 mo M VSD, PDA, coarctation of the aorta
4 1 y F VSD, pulmonary hypertension þ acute myocardial infarction
5 20 d F PDA, ASD, pneumonia
6 2 d F PDA, ASD. Tetralogy of Fallot s/p surgery
7 2 d M PDA, diaphragmatic hernia
8 36 wk M PDA, pulmonary hypertension, RDS
9 40 wk F PDA, ASD
10 37 wk M PDA, ASD, intraventricular hemorrhage
11 5 d M PDA, VSD, diaphragm defect
No. Age Sex Clinical diagnosis [cyanotic CHD (Group 2)]
12 20 d F Left heart hypoplastic syndrome
13 31 wk F Left heart hypoplastic syndrome
14 62 y M VSD Eisenmenger syndrome
No. Age Sex Clinical diagnosis [chromosomal abnormalities with CHD (Group 3)]
15 20 wk F Trisomy 13, 47, XX, þ 13 VSD
16 23 wk F Trisomy 18. 47, XX, þ 18 ASD
17 2 mo F Trisomy 21, ASD, VSD, PDA
No. Age Sex Clinical diagnosis [complex CHD (Group 4)]
18 77 d F Complex CHD, Goldenhar syndrome a
19 2 mo F Complex CHD
No. Age Sex Clinical diagnosis [controls (Group 5)]
1 7 d M Oropharyngeal immature teratoma
2 20 wk GA Body stalk syndrome
3 25 wk GA Congenital hydrocephalus
4 21 wk > GA IUFD, hemangioma of the thigh
5 38 wk GA Tracheoesophageal atresia
6 13 wk GA Congenital anomaly
7 17 wk GA Mother drug abuse
8 21 wk GA Congenital anomaly of the kidney
9 Thrombosis of the umbilical cord
10 14 þ 5 wk IUFD
ACHDZ acyanotic congenital heart disease; ASDZ atrial septal defect; CCHDZ cyanotic congenital heart disease; CHDZ congenital
heart disease; GA Z gestational age; IUFD Z intrauterine fetal death; PDA Z patent ductus arteriosus; RDS Z respiratory distress
syndrome; s/p Z status post; VSD Z ventricular septal defect.
a Goldenhar syndrome is the predominant defect of anomalies representing problems in morphogenesis of the first and second
branchial arches, sometimes accompanied by vertebral anomalies and/or ocular anomalies.
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Ethics Committee of the Kaohsiung Medical Hospital (IRB
KMUH-IRB-2013287).
IHC staining
The IHC staining was performed on 4-mm thick paraffin
sections. Paraffin sections of all samples were deparaffi-
nized, rehydrated, and autoclave treated at 121C for
10 minutes in pH 9.0 Dako target retrieval solution (Dako,
Glostrup, Denmark) to induce antigen retrieval. Endoge-
nous peroxidase in the section was blocked by incubation in
3% hydrogen peroxide for 5 minutes. The sections were
incubated (at room temperature for 1 hour) with primary
antibody including HIF-1a (1:200; H-206, Santa cruz
Biotechnology Inc., CA, USA), VEGF (1: 400; A-20, SantaCruz), CD34 (1:200; M715, Dako, Glostrup, Denmark), iNOS
(1:100; ab15323-500, Abcam, Cambridge, MA, UK), and ET-1
(1: 200; HPA031976, Sigma Life Science, Singapore). The
Dako REAL Envision Detection kit was then applied for
30 minutes. Finally, sections were incubated in 3,30-dia-
minobenzidine for 5 minutes, followed by Mayer’s hema-
toxylin counterstaining and mounting. Negative controls
were obtained by replacing the primary antibodies with
nonimmune serum.
Interpretation of IHC analysis
Stained IHC slides were scanned, inspected, serialized, and
digitalized using a panoramic digital slide scanner (3DHIS-
TECH Ltd., Budapest, Hungary). Quantification of image
objects (e.g., nuclei or cytoplasm) and unbiased analysis of
Angiogenesis in congenital heart disease 351immunostaining results were performed using the semi-
automated image analysis software Quan Center v.1.16.2.
HIF-1a, VEGF, iNOS, and ET-1 expressions were scored by
the Allred score system [11]. Staining scores were quanti-
fied as follows:
Proportion score: 0, no staining; 1, 1% positive staining
of cytoplasm of cells; 2, 1e10% positive staining of cyto-
plasm of cells; 3, 11e33% positive staining of cytoplasm of
cells; 4, 34e66% positive staining of cytoplasm of cells; and
5, 67% positive staining of cytoplasm of cells. Intensity
score: 0, negative; 1, weak staining; 2, intermediate
staining; and 3, strong staining. Total score
(TS) Z proportion score þ intensity score; low score:
TS < 5, high score: TS  5.
Microvessel density analysis
Microvessel density (MVD) was defined as the number of
CD34-positive staining vessels per field counted in the area
of highest vascular density as described previously [12].
Individual stained microvessels were point counted at 400
magnification. Randomly selected three fields with the
highest number of blood vessels were subjected to analysis,
and the mean blood vessel density was calculated by
dividing the average number of blood vessels by the area of
the field (no. of blood vessels/1 mm2).
Statistical analysis
In this study, we used the KruskaleWallis test (a nonpara-
metric method for comparing 2 or more independent sam-
ples of equal or different sample sizes, small sample sizes,
or data are not symmetric) to analyze the differences in the
concentrations of HIF-1a, VEGF, iNOS, and ET-1 between
CHD patients and healthy persons. Statistical significance
was considered when p < 0.05. All statistical analysis was
performed using SPSS version 19 (SPSS, Chicago, IL, USA).
Results
Figure 1 shows the representative IHC staining of HIF-1a,
VEGF, iNOS, ET-1, and CD34 of autopsy cases without CHD
(Figures 1A, 1C, 1E, 1G, and 1I) in comparison with autopsy
cases with CHD (Figures 1B, 1D, 1F, 1H, and 1J). Table 2
presents the scores of HIF-1a, VEGF, iNOS, and ET-1
analyzed by the semiautomated image analysis software
and the mean MVD. Table 3 depicts the relationship of HIF-
1a, VEGF, iNOS, and ET-1 expressions between CHD and
non-CHD autopsy cases determined by the KruskaleWallis
test (nonparametric method). Overexpression of HIF-1a
(p < 0.001), iNOS (p Z 0.002), and ET-1 (p Z 0.019) were
significant in CHD autopsy cases compared with non-CHD
autopsy cases.
In our 19 CHD cases, high expression of HIF-1a was found
in all cases (100%). Statistical analysis using the Man-
teleCox method also indicated that high HIF-1a expression
had significant correlation with CHD patients’ survival
(p Z 0.013).
A high percentage of VEGF expression was found in 17 of
the 19 CHD cases (89.5%; 9 cases of ACHD, 3 cases of CCHD,
3 cases of CHD with chromosomal abnormalities, and 2cases of complex CHD). Low expression of VEGF (TS < 5)
was found in two (10.5%) of the 19 CHD cases [1 case PDA
(Case No. 9) and 1 case of bilateral intraventricular hem-
orrhage (IVH; Case No. 10)]. There was no significant dif-
ference in VEGF expression between CHD and non-CHD
autopsy cases (Table 2).
High percentage of iNOS expression was found in 15 CHD
cases [78.9%; 9 cases of ACHD, 3 cases of CCHD, 1 case of
CHD with chromosomal abnormality (Trisomy 13), and 2
cases of complex CHD]. Low expression of iNOS was found in
four CHD cases [21.1%; 1 case with PDA and ASD (Case No.
6), 1 case with congenital diaphragmatic hernia (CDH; Case
No. 7), and 2 cases with chromosomal abnormalityd-
trisomy 18 and trisomy 21 (Case Nos. 16 and 17)].
High percentage of ET-1 expression was found in 16 CHD
cases (84.2%). Low expression of ET-1 was found in three
CHD cases [1 case with PDA and ASD (Case No. 9), 1 case
with PDA, VSD, and diaphragm defect (Case No. 11), and 1
case with chromosomal abnormality (Trisomy 21; Case No.
17)].
High percentage of MVD expression (MVD > 0.5  103/
mm2 defined as high MVD) was found in 16 (84.2%) CHD
cases. MVD had a significant correlation with VEGF
expression (p Z 0.04) in our study.Discussion
Previous studies have indicated that hypoxia is a common
feature of CHD [13,14]. HIF-1a expression is induced by
cellular response to hypoxia, and it appears to be a master
transcription factor capable of inducing the expression of
genes related to autoregulation, glucose metabolism, cell
survival and proliferation, angiogenesis, energy meta-
bolism, and erythropoiesis. In this study, HIF-1a expression,
as well as three downstream target genes, VEGF, iNOS, and
ET-1, were evaluated in autopsy samples of infants with
CHD by IHC staining. Our results demonstrated that the high
expression levels of HIF-1a were significantly elevated in
patients with CHD compared with non-CHD cases, and the
downstream genes of VEGF, iNOS, and ET-1 were upregu-
lated significantly in most CHD cases. We also performed
the IHC staining in different sites (right ventricle, left
atrium, and septum). The scores of different markers in
these sites were similar to the site of the left ventricle
(data not shown). Figure S1 shows the HIF-1a, VEGF, iNOS,
ET-1, and CD34 IHC staining in the right ventricle
(see Supplementary Figures S1AeS1E online), left atrium
(see Supplementary Figures S1FeS1J online), and septum
(see Supplementary Figures S1KeS1O online), respectively.
Previous experimental and clinical studies have indi-
cated that HIF-1a plays an important role in the patho-
genesis of persistent pulmonary hypertension of the
newborn (PPHN) and CCHD [14,15]. HIF-1a protein could
also be detected in autopsy samples from patients with
acute myocardial infarction [16]. In addition, HIF-1a
expression increased in cardiomyocytes of ischemic rat
hearts [17], and chronic hypoxemia is associated with the
induction and stabilization of HIF-1a as well as its target
genes VEGF and eNOS in infants with CCHD [18]. Constitu-
tive overexpression of HIF-1a in murine heart resulted in
the attenuation of infract size and improved cardiac
Figure 1. Immunohistochemistry staining of HIF-1a, VEGF, iNOS, ET-1, and CD34 expressions in autopsy samples (A, C, E, G, and I)
without CHD and (B, D, F, H, and J) with CHD. Significantly high expressions of HIF-1a, iNOS, ET-1, and CD34 were observed in
352 H.-L. Yin et al.
Table 2 Scores of HIF-1a, VEGF, iNOS, and ET-1 analyzed
by the semiautomated image analysis software Quan Center
v.1.16.2 and mean MVD in CHD (1e19) and non-CHD (20e29)
cases.
No. HIF-1a VEGF iNOS ET-1 MVD (103/mm2)
01 8 6 8 6 1.18
02 8 8 8 5 1.35
03 8 8 6 5 1.34
04 8 6 5 5 1.22
05 6 8 5 6 0.19
06 8 8 4 5 1.02
07 6 6 2 6 0.57
08 8 5 8 5 1.05
09 6 4 8 4 1.65
10 8 4 6 5 0.06
11 7 6 8 4 0.05
12 8 8 5 5 1.14
13 8 6 8 6 1.33
14 5 7 6 5 1.39
15 8 8 5 6 0.93
16 7 6 4 5 1.26
17 6 6 2 4 1.21
18 8 6 6 7 0.69
19 7 6 7 5 0.65
20 3 4 2 3 0.08
21 3 4 2 3 0.05
22 3 6 3 4 0.25
23 3 7 2 2 0.2
24 2 8 2 5 0.16
25 2 4 2 3 0.16
26 4 4 3 3 0.06
27 3 4 3 5 0.22
28 3 7 4 5 0.3
29 4 3 3 4 0.25
CHD Z congenital heart disease; ET-1 Z endothelin-1; HIF-
1aZ hypoxia-inducible factor-1a; iNOSZ inducible nitric oxide
synthase; MVD Z microvessel density; VEGF Z vascular endo-
thelial growth factor.
Angiogenesis in congenital heart disease 353function, suggesting the involvement of HIF-1a in myocar-
dial remodeling [19]. Our IHC results also illustrated that
high expression of HIF-1a was found in all different groups
of CHD autopsy cases. Thus, HIF-1a is an important regu-
lator in patients with CHD.
VEGF is a potent stimulator of angiogenesis, which in-
duces widespread formation of collateral blood vessels as a
compensatory mechanism to achieve the adequate oxygen
supply to tissues in CCHD cases [20]. VEGF also promotes
angiogenesis and neovascularization in the myocardium
under hypoxic and ischemic conditions [21] and has been
suggested to contribute to cardiac remodeling in response
to mechanical stress [22]. Persistently higher VEGF level
may be related to the development of systemic to pulmo-
nary collateral arteries in patients with CCHD [23].
Abnormal blood vessel proliferation often occurs in patientssamples with CHD compared with non-CHD samples. CHD Z cong
inducible factor-1a; iNOS Z inducible nitric oxide synthase; VEGFwith CHD and this may represent a form of anomalous
angiogenesis, especially in the lungs or myocardium [24]. In
our study, most CHD cases were observed to have high
expression levels of VEGF. However, few cases were
observed to have low expression levels of VEGF. Prior
research indicated that IVH in premature infants might
involve dysfunction of the tight junction of the bloodebrain
barrier [25], which disrupts the choroid plexus. IVH might
injure the choroid plexus resulting in VEGF being unable to
reach its receptors, eventually leading to reduced VEGF
expression. The brain also contains multipotential stem
cells that can differentiate into glial cells to produce VEGF.
Disruption of brain tissue by IVH might also reduce VEGF
production by these glial cells. This phenomenon could
explain the low expression of VEGF in the case of CHD with
brain lesion (Case No. 10). In addition, expression levels of
VEGF did not show significant difference between CHD and
non-CHD cases. Previous research has indicated that VEGF
is expressed in multiple embryonic and fetal tissues, with
the highest levels found in the lung, kidney, and heart
during development [26]. In addition, VEGF expression in
normal infants is elevated during the neonatal period and
decreases a few months after birth [23]. Therefore, this
could explain why VEGF expression did not show a signifi-
cant difference between the CHD and non-CHD groups in
our study.
A previous study has indicated that hypoxia increased
both iNOS messenger RNA and protein levels but had no
effect on neuronal NOS levels [27]. Significant increases in
eNOS and iNOS expressions were found in pulmonary
vascular endothelial cells of patients with CHD compared
with control infants [28]. Hypoxia causes an increase in
iNOS expression in cardiac myocytes and HIF-1 is essential
for the hypoxic regulation of iNOS gene expression [29]. In
our study, a high percentage of iNOS expression was
observed in CHD cases and this showed a significant dif-
ference with non-CHD cases. This IHC staining result was
similar to those obtained with other groups using different
experimental methods. Other groups also found that iNOS
expression was significantly higher in CCHD compared with
ACHD [30], but our result did not reveal this phenomenon.
This may be due to the fewer number of CCHD autopsy
samples in this study; therefore, we could not obtain the
same result compared with other groups. Low expression of
iNOS was found in several cases in CHD (Case Nos. 6 and 7),
suggesting that immaturity of the skeletal muscle and
muscle dysfunction might alter the induction of iNOS
expression [31]. Besides, low expression of iNOS was also
found in Trisomy 18 (Case No. 16) and Trisomy 21 (Case No.
17), suggesting that chromosome abnormality (i.e., Trisomy
18 and Trisomy 21) would affect iNOS production through
cardiac abnormality [32].
A previous study pointed out that ET-1 receptor dysre-
gulation is associated with structural alteration of pulmo-
nary arteries in newborns with CDH and PPHN, suggesting
that dysregulation of ET-1 receptors may contribute to
PPHN associated with CDH [33]. Another study indicatedenital heart disease; ET-1 Z endothelin-1; HIF-1a Z hypoxia-
Z vascular endothelial growth factor.
Table 3 Factors analysis of HIF-1-a, VEGF, iNOS, ET-1, and MVD.
Group Non-CHD ACHD CCHD Chromosomal abnormalities Complex CHD p *
n 10 11 3 3 2
HIF-1-a 3.0  0.7 7.4  0.9 7.0  1.7 7.0  1.0 7.5  0.7 <0.001 *
3 8 8 7 7.5
VEGF 5.1  1.7 6.3  1.5 7.0  1.0 6.7  1.2 6.0  0.0 0.315
4 6 7 6 6
iNOS 2.6  0.7 6.2  2.0 6.3  1.5 3.7  1.5 6.5  0.7 0.002 *
2.5 6 6 4 6.5
ET-1 3.7  1.1 5.1  0.7 5.3  0.6 5.0  1.0 6.0  1.4 0.019 *
3.5 5 5 5 6
MVD 0.2  0.1 0.9  0.6 1.3  0.1 1.1  0.2 0.7  0.3
Data are presented as the mean  SD and the median.
ACHD Z acyanotic congenital heart disease; CCHD Z cyanotic congenital heart disease; CHD Z congenital heart disease; ET-
1 Z endothelin-1; HIF-1a Z hypoxia-inducible factor-1a; iNOS Z inducible nitric oxide synthase; MVD Z microvessel density;
SD Z standard deviation; VEGF Z vascular endothelial growth factor.
* KruskaleWallis tests (nonparametric method).
354 H.-L. Yin et al.that that immunoreactive endothelin-1 levels are often
elevated in children with pulmonary hypertension, and they
are strongly correlated with pulmonary vasoreactivity dur-
ing acute hypoxia. Whether elevated immunoreactive
endothelin-1 levels contribute directly to or are markers of
altered pulmonary vascular tone and reactivity in children
with pulmonary hypertension remains speculative [34].
Specific features in Down syndrome could be associated
with ET-1 injury and might cause persistent increases in ET-
1 concentration and prolong artificial respiration [35].
Hypoxia is one of the most potent inducers of ET-1 gene
expression in endothelial cells and may be the primary
cause of the increased production of ET-1 during myocar-
dial ischemia. Hypoxia induces the synthesis and secretion
of ET-1 in isolated endothelial cells by a mechanism that is
antagonized by NO and carbon monoxide and mimicked by
transition metals [36e38]. Another study also implies that a
positive feedback loop may be formed between ET-1 and
HIF-1a and this may continually promote smooth muscle
cell contraction and proliferation and contribute to the
development of pulmonary hypertension [39]. The recent
development of ET receptor antagonists as potential ther-
apeutic agents suggests that the investigation of ET re-
ceptor antagonists for the treatment of both chronic and
acute pulmonary hypertension secondary to CHD is war-
ranted [40]. In our studies, high expression of ET-1 was
found in most CHD cases and had significant difference
compared with the non-CHD cases by IHC staining. This
result is similar to other groups using different experi-
mental methods. Therefore, ET-1 could be a pathophysio-
logic regulator in CHD patients.
A previous study indicated that CCHD resulting in
chronic hypoxia might exclusively provoke angiogenesis in
the subendocardial meshwork of the heart wall, and ven-
tricular dysfunction observed in some cases of CCHD could
not be predicted by the estimation of MVD [12]. Another
study has indicated that hypoxia mediated the develop-
ment of the myocardial microvessels and the expression of
VEGF in the serum and the upregulation of VEGF in patients
with CCHD may lead to the development of myocardial
microvessels [24]. In our study, the MVD values calculatedfrom CD34 staining were significantly larger in CHD cases
compared with non-CHD cases (p < 0.05) and CD34
expression had significant correlation with VEGF
(p < 0.05). The mean MVD in CCHD is higher than ACHD in
our study and similar to previous studies [12,24]. However,
whether MVD medicated by VEGF could be a predictive
marker of ventricular dysfunction in patients with CHD
should be further studied.
In conclusion, significantly high percentages of HIF-1a,
VEGF, iNOS, and ET-1 expressions were observed in our CHD
autopsy cases. HIF-1a induced by hypoxia could play a po-
tential role in relating downstream gene expressions in CHD
patients. Upregulation of VEGF by HIF-1a could play an
important role in triggering angiogenesis to protect
myocardial cell survival in a hypoxic microenvironment.
Therefore, HIF-1a could be a significant prognosis marker in
CHD and be a prospective candidate in the development of
target therapy in cardiovascular diseases.
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